By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: NanoViricides Reports Positive Anti-viral Effect of HIV Drug
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > NanoViricides Reports Positive Anti-viral Effect of HIV Drug
BusinessPublic HealthTechnology

NanoViricides Reports Positive Anti-viral Effect of HIV Drug

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

NanoViricides (OTCBB:NNVC) announced Monday that its anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.

In a recent study with mice, the West Haven, Connecticut-based company found that the anti-viral effect of its HIVCide drug continued throughout the full 48 days of the study, despite the fact that HIVCide doses were stopped after 20 days.

The benefits of the company’s drug were sustained for at least four weeks after the last dose.

NanoViricides (OTCBB:NNVC) announced Monday that its anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.

More Read

Why Meal Planning Is Good for Your Budget & Your Health
A Call to Action from HiMSS
Reality Check Of The Healthcare Sector So Far For 2020
Ask Your Patients To Participate Through EMR!
Florida Board of Medicine Declares Arizona Homeopathic Doctor “Very, Very Dangerous”

In a recent study with mice, the West Haven, Connecticut-based company found that the anti-viral effect of its HIVCide drug continued throughout the full 48 days of the study, despite the fact that HIVCide doses were stopped after 20 days.

The benefits of the company’s drug were sustained for at least four weeks after the last dose.

HIVCide works by mimicking cellular structures to which the virus binds, specifically attacking and dismantling them.

In addition to requiring fewer doses, NanoViricides believes its HIVCide drug is superior to the current antiretroviral drug cocktails as its therapy requires a lower drug load.

The HIVCide total dosage was 1,200 milligrams per kilogram (mg/kg), eight times over the first 20 days of the study, whereas the dose in the comparative arm was 4,800 mg/kg, continued throughout the full 48 days of the trial.

NanoViricides said the HIV viral load, or the measured severity of viral infection, was the same in both arms of the animal study. The HIVCide group also displayed no side effects or adverse effects.

“There are several huge problems with the current HIV therapy,” explained CEO Eugene Seymour.

“These include side effects, viral resistance, and patient compliance issues; all of which can lead to discontinuation of therapy.

“A drug that is administered once a week or less frequently, and continues to work without adverse side effects, would be of great benefit to patients.”

The study was performed on mice whose lymphocytes and immune system cells had been replaced by human cells, where the HIV infection occurred.

Importantly, the development stage company also noted that drug metabolism in mice is known to be much faster than human metabolism. Should the drug be effective in human trials, the HIVCide treatment could become a once-per-week or twice-per-month dosage.

“If our humanized mouse study results are confirmed in human clinical trials, this would be a great advance in HIV/AIDS therapy,” Seymour added.

“If the results hold up in human studies, we think that we would have a ‘functional cure’ of HIV/AIDS.”

NanoViricides, which is also developing drugs against viral diseases like H1N1 swine flu, H5N1 bird flu, Herpes, Hepatitis C, Rabies and Dengue fever, among others, saw its stock on the OTC Bulletin Board spike 14.02% today, to trade at $1.22 per share as of 12:39 pm EDT.–Olivia D’Orazio

 

TAGGED:healthcare businessHIVmedical technologynanoviricidespharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

United4Health-CHF
Global HealthcarePolicy & LawTechnology

Major EU Remote Monitoring Pilot Results

March 18, 2016
Image
DiagnosticsRadiologyTechnology

RSNA 2012: Some Gain in Detecting Pain to the Brain

November 27, 2012

Slush Fund: What Did They Know? When Did They Know It?

March 10, 2011
Policy & LawPublic Health

Six Industries That Rely On The FDA Heavily

April 22, 2020
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?